X-Linked Hypophosphatemia Market: By Treatment (Medication, Surgical, or Orthopedic Treatment), End User (Hospitals and Clinics, Research Centers) & Region (Americas, Europe, Asia-Pacific & RoW) - Forecast till 2030

1 Executive Summary

2 Market Introduction

2.1 Scope of the Study 13

2.2 Research Objective 13

2.3 List of Assumptions 14

3 Research Methodology

3.1 Research Methodology - X-Linked Hypophosphatemia Market 15

3.2 Data Mining 16

3.3 Secondary Research 16

3.3.1 Data points received from the secondary research 17

3.4 Primary Research 17

3.4.1 Data points received from surgeons, & consulting physicians 18

3.4.2 Data points received from the manufacturer 19

3.5 Forecasting Techniques 19

3.6 Research Methodology for Market Size Estimation X-Linked Hypophosphatemia Market: 20

3.6.1 Assumptions 21

3.7 Data Triangulation 22

3.8 Validation 22

4 Market Dynamics

4.1 Overview 23

4.2 Drivers 24

4.2.1 Increasing Prevalence Rate of XLH 24

4.2.2 Growing Awareness about XLH 24

4.2.3 Increasing Research 24

4.2.4 Driver Impact Analysis 25

4.3 Restraints 26

4.3.1 Side-Effects Associated with Burosumab 26

4.3.2 High Cost of Burosumab 26

4.3.3 Limited Availability of Treatment Options 26

4.3.4 Restraint Impact Analysis 27

4.4 Opportunity 28

4.4.1 Recent Regulatory Approvals 28

5 Market Factor Analysis

5.1 Value Chain Analysis 29

5.1.1 Overview 29

5.1.2 R&D 29

5.1.3 Manufacturing 29

5.1.4 Distribution and Sales 29

5.1.5 Post-Sales Monitoring 30

5.2 Porter’s Five Forces Model 31

5.2.1 Overview 31

5.2.2 Bargaining Power of Suppliers 32

5.2.3 Bargaining Power of Buyers 32

5.2.4 The threat of New Entrants 32

5.2.5 Threat of Substitutes 32

5.2.6 Intensity of Rivalry 32

6 X-Linked Hypophosphatemia Market, by Treatment

6.1 Introduction 33

6.2 Medication 34

6.3 Surgical or Orthopedic Treatment 34

7 X-Linked Hypophosphatemia Market, by End User

7.1 Introduction 35

7.2 Hospitals and Clinics 36

7.3 Research Centers 36

8 Global X-Linked Hypophosphatemia Market, by Region

8.1 Introduction 37

8.2 Americas 39

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.2.1 North America 40

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.2.1.1 US 41

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.2.1.2 Canada 42

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.2.2 South America 42

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3 Europe 43

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.1 Germany 44

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.2 France 45

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.3 UK 45

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.4 Italy 46

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.5 Spain 46

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.6 Rest of Europe 47

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4 Asia-Pacific 48

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.1 China 49

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.2 Japan 50

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.3 India 50

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.4 South Korea 51

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.5 Australia 51

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.6 Rest of Asia-Pacific 52

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.5 RoW 53

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

9 Competitive landscape

9.1 Introduction 54

9.2 Key developments 55

10 Company Profiles

10.1 Ultragenyx Pharmaceutical 57

10.1.1 Company Overview 57

10.1.2 Financial Overview 57

10.1.3 Products/Services Offered 58

10.1.4 Key Developments 58

10.1.5 SWOT Analysis 58

10.1.6 Key Strategies 59

10.2 Validus Pharmaceuticals LLC 60

10.2.1 Company Overview 60

10.2.2 Financial Overview 60

10.2.3 Products/Services Offered 60

10.2.4 Key Developments 60

10.2.5 SWOT Analysis 60

10.2.6 Key Strategies 61

10.3 Prospec-Tany Technogene Ltd 62

10.3.1 Company Overview 62

10.3.2 Financial Overview 62

10.3.3 Products/Services Offered 62

10.3.4 Key Developments 62

10.3.5 SWOT Analysis 63

10.3.6 Key Strategies 63

10.4 Merck KGaA 64

10.4.1 Company Overview 64

10.4.2 Financial Overview 64

10.4.3 Products/Services Offered 64

10.4.4 Key Developments 65

10.4.5 SWOT Analysis 65

10.4.6 Key Strategies 65

10.5 Zeria Pharmaceutical Co., Ltd 66

10.5.1 Company Overview 66

10.5.2 Financial Overview 66

10.5.3 Products/Services Offered 66

10.5.4 Key Developments 66

10.5.5 SWOT Analysis 67

10.5.6 Key Strategies 67

10.6 Smith & Nephew 68

10.6.1 Company Overview 68

10.6.2 Financial Overview 68

10.6.3 Products/Services Offered 68

10.6.4 Key Developments 69

10.6.5 SWOT Analysis 69

10.6.6 Key Strategies 69

10.7 Narang Medical Limited 70

10.7.1 Company Overview 70

10.7.2 Financial Overview 70

10.7.3 Products/Services Offered 70

10.7.4 Key Developments 70

10.7.5 SWOT Analysis 71

10.7.6 Key Strategies 71

10.8 Eli Lilly and Company 72

10.8.1 Company Overview 72

10.8.2 Financial Overview 72

10.8.3 Products/Services Offered 72

10.8.4 Key Developments 73

10.8.5 SWOT Analysis 73

10.8.6 Key Strategies 73

10.9 F. Hoffmann-La Roche Ltd 74

10.9.1 Company Overview 74

10.9.2 Financial Overview 74

10.9.3 Products/Services Offered 74

10.9.4 Key Developments 75

10.9.5 SWOT Analysis 75

10.9.6 Key Strategies 75

10.10 Illumina, Inc. 76

10.10.1 Company Overview 76

10.10.2 Financial Overview 76

10.10.3 Products/Services Offered 77

10.10.4 Key Developments 77

10.10.5 SWOT Analysis 78

10.10.6 Key Strategies 78

10.11 Biomedica Medizinprodukte GmbH 79

10.11.1 Company Overview 79

10.11.2 Financial Overview 79

10.11.3 Products/Services Offered 79

10.11.4 Key Developments 79

10.11.5 SWOT Analysis 79

10.11.6 Key Strategies 80

10.12 QIAGEN 81

10.12.1 Company Overview 81

10.12.2 Financial Overview 81

10.12.3 Products/Services Offered 82

10.12.4 Key Developments 82

10.12.5 SWOT Analysis 82

10.12.6 Key Strategies 82

11 Appendix

11.1 References 83

11.2 Related Reports 83

12 List of Tables

TABLE 1 LIST OF ASSUMPTIONS 14

TABLE 2 PORTER’S FIVE FORCES ANALYSIS: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET 31

TABLE 3 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 33

TABLE 4 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR MEDICATION, BY REGION 2020–2027 (USD THOUSANDS) 34

TABLE 5 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR SURGICAL OR ORTHOPEDIC TREATMENT, BY REGION 2020–2027

(USD THOUSANDS) 34

TABLE 6 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 35

TABLE 7 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR HOSPITALS AND CLINICS, BY REGION 2020–2027 (USD THOUSANDS) 36

TABLE 8 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR RESEARCH CENTERS, BY REGION 2020–2027 (USD THOUSANDS) 36

TABLE 9 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 2020–2027 (USD THOUSANDS) 38

TABLE 10 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 2020–2027 (USD THOUSANDS) 39

TABLE 11 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 39

TABLE 12 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 40

TABLE 13 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY 2020–2027 (USD THOUSANDS) 40

TABLE 14 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 41

TABLE 15 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 41

TABLE 16 US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 41

TABLE 17 US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 41

TABLE 18 CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 42

TABLE 19 CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 42

TABLE 20 SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 42

TABLE 21 SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 42

TABLE 22 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 2020–2027 (USD THOUSANDS) 43

TABLE 23 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 44

TABLE 24 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 44

TABLE 25 GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 44

TABLE 26 GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 44

TABLE 27 FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 45

TABLE 28 FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 45

TABLE 29 UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 45

TABLE 30 UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 45

TABLE 31 ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 46

TABLE 32 ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 46

TABLE 33 SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 46

TABLE 34 SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 46

TABLE 35 REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 47

TABLE 36 REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 47

TABLE 37 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 2020–2027 (USD THOUSANDS) 48

TABLE 38 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 49

TABLE 39 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 49

TABLE 40 CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 49

TABLE 41 CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 49

TABLE 42 JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 50

TABLE 43 JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 50

TABLE 44 INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 50

TABLE 45 INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 50

TABLE 46 SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 51

TABLE 47 SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 51

TABLE 48 ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 51

TABLE 49 ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 51

TABLE 50 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 52

TABLE 51 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 52

TABLE 52 ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020–2027 (USD THOUSANDS) 53

TABLE 53 ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020–2027 (USD THOUSANDS) 53

TABLE 54 KEY DEVELOPMENTS, BY PLAYERS IN THE MARKET 55

13 List of Figures

FIGURE 1 MARKET SYNOPSIS 12

FIGURE 2 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET: STRUCTURE 14

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 21

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL GROWTH HORMONE MARKET 23

FIGURE 5 DRIVER IMPACT ANALYSIS 25

FIGURE 6 RESTRAINT IMPACT ANALYSIS 27

FIGURE 7 SUPPLY CHAIN: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET 29

FIGURE 8 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2020 & 2027 (USD THOUSANDS) 33

FIGURE 9 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2020 & 2027 (USD THOUSANDS) 36

FIGURE 10 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2020 (%) 38

FIGURE 11 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2020 (%) 39

FIGURE 12 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY 2020 (%) 40

FIGURE 13 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2020 (%) 43

FIGURE 14 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2020 (%) 48

FIGURE 15 MAJOR PLAYERSCATEGORY-WISE SHARE OF KEY DEVELOPMENTS 56